GB201121308D0 - Process - Google Patents

Process

Info

Publication number
GB201121308D0
GB201121308D0 GBGB1121308.9A GB201121308A GB201121308D0 GB 201121308 D0 GB201121308 D0 GB 201121308D0 GB 201121308 A GB201121308 A GB 201121308A GB 201121308 D0 GB201121308 D0 GB 201121308D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1121308.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuur Therapeutics Ltd
Original Assignee
Cell Medica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45560301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201121308(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cell Medica Ltd filed Critical Cell Medica Ltd
Priority to GBGB1121308.9A priority Critical patent/GB201121308D0/en
Publication of GB201121308D0 publication Critical patent/GB201121308D0/en
Priority to PCT/GB2012/053113 priority patent/WO2013088147A1/en
Priority to AU2012351843A priority patent/AU2012351843B2/en
Priority to HK15103776.7A priority patent/HK1203210B/en
Priority to ES12815750T priority patent/ES2626492T5/es
Priority to JP2014546633A priority patent/JP6203745B2/ja
Priority to HK15103777.6A priority patent/HK1203219A1/xx
Priority to EP12815750.0A priority patent/EP2791163B2/en
Priority to PCT/GB2012/053114 priority patent/WO2013088148A2/en
Priority to AU2012351842A priority patent/AU2012351842B2/en
Priority to EP12816092.6A priority patent/EP2791323A2/en
Priority to US14/364,626 priority patent/US20140341951A1/en
Priority to JP2014546634A priority patent/JP2015505852A/ja
Priority to US14/364,621 priority patent/US20150044258A1/en
Priority to US14/981,440 priority patent/US20160184361A1/en
Priority to JP2017132663A priority patent/JP6657145B2/ja
Priority to US16/016,305 priority patent/US11963979B2/en
Priority to JP2019203285A priority patent/JP2020022505A/ja
Priority to US17/586,698 priority patent/US20220152111A1/en
Priority to JP2022066435A priority patent/JP2022089916A/ja
Priority to JP2023179166A priority patent/JP2023174861A/ja
Priority to US19/361,743 priority patent/US20260042987A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/24—Gas permeable parts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/18011—Nimaviridae
    • C12N2710/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Sustainable Development (AREA)
  • Clinical Laboratory Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Materials For Medical Uses (AREA)
GBGB1121308.9A 2011-12-12 2011-12-12 Process Ceased GB201121308D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB1121308.9A GB201121308D0 (en) 2011-12-12 2011-12-12 Process
US14/364,621 US20150044258A1 (en) 2011-12-12 2012-12-12 Process for t cell expansion
AU2012351843A AU2012351843B2 (en) 2011-12-12 2012-12-12 Method of treatment employing therapeutic T cell product from mobilised donors
AU2012351842A AU2012351842B2 (en) 2011-12-12 2012-12-12 Process for T cell expansion
JP2014546634A JP2015505852A (ja) 2011-12-12 2012-12-12 動員ドナーからの治療用ｔ細胞生成物を用いる処置方法
HK15103776.7A HK1203210B (en) 2011-12-12 2012-12-12 Process for t cell expansion
ES12815750T ES2626492T5 (en) 2011-12-12 2012-12-12 Process for t cell expansion
JP2014546633A JP6203745B2 (ja) 2011-12-12 2012-12-12 Ｔ細胞増殖のためのプロセス
HK15103777.6A HK1203219A1 (en) 2011-12-12 2012-12-12 Method of treatment employing therapeutic t cell product from mobilised donors
EP12815750.0A EP2791163B2 (en) 2011-12-12 2012-12-12 Process for t cell expansion
PCT/GB2012/053114 WO2013088148A2 (en) 2011-12-12 2012-12-12 Method of treatment employing therapeutic t cell product from mobilised donors
PCT/GB2012/053113 WO2013088147A1 (en) 2011-12-12 2012-12-12 Process for t cell expansion
EP12816092.6A EP2791323A2 (en) 2011-12-12 2012-12-12 Method of treatment employing therapeutic t cell product from mobilised donors
US14/364,626 US20140341951A1 (en) 2011-12-12 2012-12-12 Method of treatment employing therapeutic t cell product from mobilised donors
US14/981,440 US20160184361A1 (en) 2011-12-12 2015-12-28 Method of treatment employing therapeutic t cell product from mobilised donors
JP2017132663A JP6657145B2 (ja) 2011-12-12 2017-07-06 Ｔ細胞増殖のためのプロセス
US16/016,305 US11963979B2 (en) 2011-12-12 2018-06-22 Process for T cell expansion
JP2019203285A JP2020022505A (ja) 2011-12-12 2019-11-08 Ｔ細胞増殖のためのプロセス
US17/586,698 US20220152111A1 (en) 2011-12-12 2022-01-27 Process for t cell expansion
JP2022066435A JP2022089916A (ja) 2011-12-12 2022-04-13 Ｔ細胞増殖のためのプロセス
JP2023179166A JP2023174861A (ja) 2011-12-12 2023-10-17 Ｔ細胞増殖のためのプロセス
US19/361,743 US20260042987A1 (en) 2011-12-12 2025-10-17 Process for t cell expansion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1121308.9A GB201121308D0 (en) 2011-12-12 2011-12-12 Process

Publications (1)

Publication Number Publication Date
GB201121308D0 true GB201121308D0 (en) 2012-01-25

Family

ID=45560301

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1121308.9A Ceased GB201121308D0 (en) 2011-12-12 2011-12-12 Process

Country Status (8)

Country Link
US (6) US20140341951A1 (https=)
EP (2) EP2791163B2 (https=)
JP (6) JP6203745B2 (https=)
AU (2) AU2012351843B2 (https=)
ES (1) ES2626492T5 (https=)
GB (1) GB201121308D0 (https=)
HK (1) HK1203219A1 (https=)
WO (2) WO2013088148A2 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
CN104411819B (zh) * 2012-06-11 2019-05-10 威尔逊沃夫制造公司 用于过继细胞疗法的改进的细胞培养方法
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
GB201509202D0 (en) * 2015-05-28 2015-07-15 Ge Healthcare Bio Sciences Ab Semi-static cell culture
HK1254397A1 (zh) 2015-06-26 2019-07-19 纪念斯隆-凯特林癌症中心 通过t细胞疗法治疗cmv视网膜炎的方法
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
US11473059B2 (en) 2015-10-22 2022-10-18 Lucas Bio Co. Ltd. Method for enrichment and expansion of virus antigen-specific T cells
US11248238B2 (en) 2015-10-22 2022-02-15 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
EP3368051B1 (en) 2015-10-30 2026-04-15 Children's National Medical Center Generating hpv antigen-specific t cells from a naive t cell population
US20190032013A1 (en) * 2016-01-29 2019-01-31 Tract Therapeutics, Inc. Immune cell selection, expansion, and use
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
CN109843921B (zh) 2016-07-07 2023-05-26 艾欧凡斯生物治疗公司 程序性死亡1配体1(pd-l1)结合蛋白及其应用方法
MX2019004707A (es) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11401507B2 (en) 2016-11-17 2022-08-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
JOP20190224A1 (ar) * 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US10821134B2 (en) 2017-05-17 2020-11-03 Board Of Regents, The University Of Texas System BK virus specific T cells
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
EP3635097A1 (en) * 2017-06-05 2020-04-15 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
US20210130779A1 (en) 2018-04-27 2021-05-06 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2019217753A1 (en) * 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
FR3082524B1 (fr) * 2018-06-18 2022-03-25 Univ Paris Sud Methode de stratification du risque de nephropathie a bk-virus apres transplantation renale
TW202039830A (zh) 2018-11-05 2020-11-01 美商艾歐凡斯生物治療公司 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
AU2019375997A1 (en) 2018-11-08 2021-06-03 Neximmune, Inc. T cell compositions with improved phenotypic properties
CN120172958A (zh) 2019-04-12 2025-06-20 C4医药公司 Ikaros和aiolos的三环降解物
US10772914B1 (en) 2019-04-18 2020-09-15 Baylor College Of Medicine EBV-specific immune cells
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
US12159700B2 (en) 2020-04-22 2024-12-03 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US11781100B2 (en) 2020-12-03 2023-10-10 Applied Materials, Inc. All-in-one bioreactor for therapeutic cells manufacturing
US20240060044A1 (en) * 2021-02-25 2024-02-22 Senthilkumar NATESAN A novel method of generating t cells from peripheral blood precursors and their uses thereof
AU2022246174A1 (en) 2021-03-25 2023-09-14 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
EP4373919A1 (en) 2021-07-18 2024-05-29 Gamida-Cell Ltd. Therapeutic nk cell populations
WO2023159088A1 (en) * 2022-02-15 2023-08-24 Marker Therapeutics, Inc. Compositions and methods for antigen-specific t cell expansion
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
US20260092248A1 (en) * 2022-09-15 2026-04-02 Life Technologies Corporation Bioreactors operable in static and dynamic modes and methods of use
WO2024145700A1 (pt) * 2023-01-02 2024-07-11 Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein Método de expansão de linfócitos vírus-específicos, composição e uso de uma composição
US20250144143A1 (en) * 2023-11-06 2025-05-08 Immunitybio, Inc. Virally Educated T cells

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641628A (en) 1989-11-13 1997-06-24 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal DNA
WO1994002156A1 (en) 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
US6821778B1 (en) 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
WO1995024217A1 (en) 1994-03-08 1995-09-14 Dana-Farber Cancer Institute Methods for modulating t cell unresponsiveness
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
PT772624E (pt) 1994-04-06 2001-03-30 Immunex Corp Interleucina-15
PT804210E (pt) 1994-05-16 2003-04-30 Roche Diagnostics Gmbh Processo de imunomodelacao por transferencia adoptiva de linfocitos t citotoxicos especificos de um antigenio
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
PT747481E (pt) 1995-06-06 2002-05-31 Organon Teknika Bv Peptidos do virus de epstein-barr e anticorpos contra estes peptidos
FR2745185B1 (fr) 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
US6699477B2 (en) 1996-05-24 2004-03-02 The Council Of The Queensland Institute Of Medical Research EBV CTL epitopes
US5962318A (en) 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
WO1998033888A1 (en) 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
US6528307B1 (en) 1997-04-25 2003-03-04 The Wistar Institute Of Anatomy And Biology Cytolytic T-cell clones against colorectal carcinoma
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
ATE428769T1 (de) 1997-10-27 2009-05-15 Univ Rockefeller Methode und zusammensetzung zur herstellung von reifen dendritischen zellen
US20020155108A1 (en) 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
WO2000050569A1 (en) 1999-02-24 2000-08-31 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
US6828147B1 (en) 1999-02-24 2004-12-07 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
US7005131B1 (en) 1999-08-13 2006-02-28 The Rockefeller University Protective antigen of Epstein Barr Virus
US20150037297A1 (en) 1999-08-30 2015-02-05 David S Terman Sickled Erythrocytes and Progenitors Target Cytotoxics to Tumors
AU2425801A (en) 1999-11-24 2001-06-04 Ernest G. Hope Anti-angiogenic cellular agent for cancer therapy
DE10009341A1 (de) 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
DK2336187T3 (en) 2000-06-19 2016-08-22 Beth Israel Deaconess Medical Ct Inc Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations
AU2001288863A1 (en) 2000-09-15 2002-03-26 Ortho-Mcneil Pharmaceutical, Inc. Compositions and methods for inducing specific cytolytic t cell responses
EP1229043A1 (en) 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
GB0107628D0 (en) 2001-03-27 2001-05-16 Avidex Ltd Substances
US20040022761A1 (en) 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
ATE438710T1 (de) 2001-05-15 2009-08-15 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
UA75429C2 (en) 2001-09-28 2006-04-17 Mowing blade
EP1444330A1 (en) 2001-11-07 2004-08-11 Kirin Beer Kabushiki Kaisha Expansion of t cells in vitro and expanded t cell populations
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
RU2313365C2 (ru) 2001-11-29 2007-12-27 Дандрит Байотек А/С Фармацевтическая композиция для индукции иммунной реакции у человека
US20040096457A1 (en) 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2004041849A1 (en) 2002-11-07 2004-05-21 The Council Of The Queensland Institute Of Medical Research Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
AU2002953238A0 (en) 2002-12-09 2003-01-02 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland In vitro immunization
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
CN101120083B (zh) 2003-10-08 2013-03-27 威尔森沃尔夫制造公司 利用透气性材料进行细胞培养的方法及装置
US20050221481A1 (en) 2004-03-30 2005-10-06 Istituto Superiore Di Sanita' Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2
US7785806B2 (en) 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
US20060045883A1 (en) 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
JP4731867B2 (ja) 2004-10-01 2011-07-27 国立大学法人三重大学 Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法
WO2006099448A2 (en) 2005-03-14 2006-09-21 University Of Iowa Research Foundation Accelerated cd8+ t-cell memory after dendritic cell vaccination
EP1712615A1 (en) 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
ES2334936T3 (es) 2005-04-20 2010-03-17 F. Hoffmann-La Roche Ag Metodo de identificacion de epitopos relacionados con la inmunogenicidad en biofarmacos.
WO2006124412A2 (en) 2005-05-11 2006-11-23 The Trustees Of The University Of Pennsylvania Methods for the rapid expansion of antigen specific t-cells
US20070003531A1 (en) 2005-06-30 2007-01-04 University Of Connecticut Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes
US20100035282A1 (en) 2005-08-03 2010-02-11 Maria Chiara Bonini Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes
JP4824389B2 (ja) 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
JP5492418B2 (ja) 2005-11-18 2014-05-14 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法
PL1989544T3 (pl) 2006-03-02 2012-01-31 Antitope Ltd Testy na komórkach T
US20070243549A1 (en) 2006-04-12 2007-10-18 Biocept, Inc. Enrichment of circulating fetal dna
WO2008025992A2 (en) 2006-09-01 2008-03-06 Cambridge Enterprise Limited Methods of expanding non-effector cd8 t-cell populations
EP2091961A4 (en) 2006-11-22 2009-12-09 Univ Arkansas IMMUNOTHERAPY AGAINST CANCER WITH MULTIPPITOP-PEPTIDE-LOADED DENDRITIC CELLS
AU2007332869B2 (en) 2006-12-07 2012-10-11 Wilson Wolf Manufacturing, LLC Highly efficient gas permeable devices and methods for culturing cells
DK2117571T3 (en) 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogen activator receptor epitope
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
CA2700618A1 (en) 2007-09-27 2009-04-02 The Board Of Trustees Of The University Of Arkansas Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
US20100254958A1 (en) 2007-10-24 2010-10-07 Anne Letsch Antigen-Specific T-Cell Preparations from Bone Marrow
JP2011502484A (ja) 2007-11-01 2011-01-27 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用
EP2065462A1 (en) 2007-11-27 2009-06-03 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens
EP2321407A4 (en) 2008-09-11 2012-07-18 Univ Florida SYSTEM AND METHOD FOR THE PRODUCTION OF T-CELLS
CN101824400B (zh) 2009-03-05 2012-08-08 中国科学院微生物研究所 一种放大增殖抗原特异性t细胞的方法
EP3101122B1 (en) * 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
JP5833443B2 (ja) 2009-08-29 2015-12-16 株式会社バイオメッドコア 抗原特異的ｔ細胞誘導能測定法
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US8809050B2 (en) 2009-12-08 2014-08-19 Wilson Wolf Manufacturing Methods of cell culture for adoptive cell therapy
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
US9114100B2 (en) 2010-05-17 2015-08-25 Duke University Methods of treatment using ex vivo expansion of cord blood T cells
EP2600890A1 (en) 2010-08-04 2013-06-12 Instituto Europeo di Oncologia S.r.l. Method of antigen loading for immunotherapy
US8741642B2 (en) 2010-10-22 2014-06-03 Virginia Commonwealth University Methods for producing autologous immune cells resistant to myeloid-derived suppressor cells effects
EP2453243A1 (en) 2010-11-11 2012-05-16 Cosmo S.p.A. Method for the diagnosis and/or follow up of the evolution of a tumor
US20130045491A1 (en) 2011-07-19 2013-02-21 Derya Unutmaz Methods for activating t cells
AU2012305931B2 (en) 2011-09-08 2017-09-07 Yeda Research And Development Co. Ltd Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
CN104769104A (zh) 2011-12-12 2015-07-08 细胞药物有限公司 扩大t细胞的方法
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
US20130217122A1 (en) 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
HK1207667A1 (en) 2012-05-08 2016-02-05 Western University Of Health Sciences Standardized ex vivo platforms for the antigen-specific expansion of cd4+ t cell populations
US10357515B2 (en) 2013-11-22 2019-07-23 Cellectis Method for generating batches of allogeneic T-cells with averaged potency
JP5870082B2 (ja) 2013-12-19 2016-02-24 住友ゴム工業株式会社 重荷重用タイヤ
US20160341718A1 (en) 2014-01-21 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for testing t cell priming efficacy in a subject
MY189857A (en) 2014-11-05 2022-03-14 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line and donor thereof for adoptive cellular therapy
WO2016073595A1 (en) 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
IL294055A (en) 2015-03-20 2022-08-01 Childrens Nat Medical Ct Generating virus or other antigen-specific t cells from a naive t cell population
HK1254397A1 (zh) 2015-06-26 2019-07-19 纪念斯隆-凯特林癌症中心 通过t细胞疗法治疗cmv视网膜炎的方法
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
MX2018013959A (es) 2016-05-25 2019-08-22 Council Queensland Inst Medical Res Metodos para tratar enfermedad autoinmune usando celulas t alogenicas.
AU2017326173B2 (en) 2016-09-16 2022-08-18 Baylor College Of Medicine Platform for activation and expansion of virus-specific T-cells
US20200172864A1 (en) 2016-09-26 2020-06-04 Tessa Therapeutics Ltd. T Cell Expansion Method
WO2018232467A1 (en) 2017-06-22 2018-12-27 The Westmead Institute for Medical Research Adoptive t cell therapy 2
JP2020533688A (ja) 2017-09-06 2020-11-19 ナント ホールディングス アイピー，エルエルシー Ｈｌａ組織照合およびそのための方法
IL286629B2 (en) 2019-03-25 2024-10-01 Baylor College Medicine Multi-respiratory virus antigen-specific t cells and methods of making and using the same therapeutically
TWI777160B (zh) 2019-05-08 2022-09-11 美商百歐恩泰美國公司 T細胞製備組合物及方法
AU2020297019A1 (en) 2019-06-20 2022-02-17 Janssen Sciences Ireland Unlimited Company Carbohydrate nanocarrier delivery of hepatitis B virus (HBV) vaccines
US20220257654A1 (en) 2019-07-23 2022-08-18 Baylor College Of Medicine Antigen-specific t cell banks and methods of making and using the same therapeutically
MX2022001322A (es) 2019-07-29 2022-05-24 Baylor College Medicine Bancos de células t específicas de antígeno y métodos para fabricar y usar los mismos terapéuticamente.
AU2020333654A1 (en) 2019-08-16 2022-03-17 Baylor College Of Medicine Third party virus-specific T cell compositions, and methods of making and using the same in anti-viral prophylaxis
US20230028788A1 (en) 2019-12-23 2023-01-26 Baylor College Of Medicine T cell performance assay as a prognostic factor for clinical outcome
WO2021189084A1 (en) 2020-03-20 2021-09-23 Baylor College Of Medicine Sars-cov2-specific t cell compositions and their use in treating and preventing coronavirus and other respiratory virus infections
EP3974029A1 (en) 2020-09-25 2022-03-30 Universidad Autónoma de Madrid Memory t cells as adoptive cell therapy for viral infections
WO2023159088A1 (en) 2022-02-15 2023-08-24 Marker Therapeutics, Inc. Compositions and methods for antigen-specific t cell expansion

Also Published As

Publication number Publication date
AU2012351842A1 (en) 2014-08-07
AU2012351843A1 (en) 2014-07-31
JP6657145B2 (ja) 2020-03-04
JP2023174861A (ja) 2023-12-08
JP6203745B2 (ja) 2017-09-27
WO2013088148A2 (en) 2013-06-20
ES2626492T3 (es) 2017-07-25
EP2791163B2 (en) 2024-11-27
US20150044258A1 (en) 2015-02-12
JP2017169594A (ja) 2017-09-28
WO2013088148A3 (en) 2013-09-06
EP2791323A2 (en) 2014-10-22
JP2015505852A (ja) 2015-02-26
US11963979B2 (en) 2024-04-23
US20140341951A1 (en) 2014-11-20
US20160184361A1 (en) 2016-06-30
AU2012351842B2 (en) 2016-05-26
JP2022089916A (ja) 2022-06-16
EP2791163A1 (en) 2014-10-22
US20220152111A1 (en) 2022-05-19
ES2626492T8 (es) 2018-07-13
HK1203210A1 (en) 2015-10-23
US20190134092A1 (en) 2019-05-09
AU2012351843B2 (en) 2016-05-12
WO2013088147A1 (en) 2013-06-20
HK1203219A1 (en) 2015-10-23
EP2791163B1 (en) 2017-03-01
JP2020022505A (ja) 2020-02-13
US20260042987A1 (en) 2026-02-12
ES2626492T5 (en) 2025-04-15
JP2015501653A (ja) 2015-01-19

Similar Documents

Publication Publication Date Title
GB201121308D0 (en) Process
GB201103499D0 (en) Process
GB201111595D0 (en) Improved process
GB201107072D0 (en) Process
PL2793599T3 (pl) Sposób
GB201218123D0 (en) Process
ZA201305221B (en) Process
GB201121557D0 (en) Process
GB201112051D0 (en) Process
GB201107073D0 (en) Process
IL229126A0 (en) process
GB201115218D0 (en) Novel process
GB201218121D0 (en) Process
GB201218124D0 (en) Process
PT2726454T (pt) Processo
GB201112370D0 (en) Process
GB201103092D0 (en) Process
GB201107221D0 (en) Process
GB201105537D0 (en) New process
SG11201403684YA (en) Process
GB2493491B (en) Process
GB201208567D0 (en) Process
GB201108511D0 (en) Process
GB201107198D0 (en) Process
GB201108522D0 (en) Process

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)